Bausch + Lomb Corp
F:S2L
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
B
|
Bausch + Lomb Corp
F:S2L
|
CA |
|
M
|
Murata Manufacturing Co Ltd
XBER:MUR1
|
JP |
|
Aisan Industry Co Ltd
TSE:7283
|
JP |
|
Hitachi Ltd
F:HIA1
|
JP |
|
Aritzia Inc
TSX:ATZ
|
CA |
Bausch + Lomb Corp
Bausch + Lomb makes eye-care products for people who need help seeing, protecting, or treating their eyes. Its lineup includes contact lenses, lens care products, surgical devices and implants used in eye procedures, and prescription and over-the-counter eye medicines. The company sells to consumers, eye doctors, hospitals, and surgery centers, so it sits in both the everyday vision-care market and the specialist ophthalmology market. The company makes money by selling products through retailers, eye-care professionals, and medical institutions, and by supplying recurring consumables such as contact lenses, cleaning solutions, and prescription therapies. It also earns revenue from surgical equipment and implants used in cataract and other eye surgeries. This mix gives it both repeat consumer demand and medical demand tied to clinical procedures. What makes Bausch + Lomb different is that it is not just a branded consumer health company or just a medical-device maker. It bridges both sides of eye care, from the products people use at home to the tools doctors use in the operating room. That position gives it a direct role in the full eye-care value chain, serving patients, eye-care professionals, and surgical teams with products aimed at vision correction and eye health.
Bausch + Lomb makes eye-care products for people who need help seeing, protecting, or treating their eyes. Its lineup includes contact lenses, lens care products, surgical devices and implants used in eye procedures, and prescription and over-the-counter eye medicines. The company sells to consumers, eye doctors, hospitals, and surgery centers, so it sits in both the everyday vision-care market and the specialist ophthalmology market.
The company makes money by selling products through retailers, eye-care professionals, and medical institutions, and by supplying recurring consumables such as contact lenses, cleaning solutions, and prescription therapies. It also earns revenue from surgical equipment and implants used in cataract and other eye surgeries. This mix gives it both repeat consumer demand and medical demand tied to clinical procedures.
What makes Bausch + Lomb different is that it is not just a branded consumer health company or just a medical-device maker. It bridges both sides of eye care, from the products people use at home to the tools doctors use in the operating room. That position gives it a direct role in the full eye-care value chain, serving patients, eye-care professionals, and surgical teams with products aimed at vision correction and eye health.
Top line: Bausch + Lomb reported first-quarter revenue of $1.244 billion, up 6% year over year in constant currency, with strong performance in Pharmaceuticals and Vision Care partly offset by a softer Surgical quarter.
Profitability: Adjusted EBITDA rose 59% year over year to $200 million, with margin expanding to 16.1%, showing the company is converting revenue growth into much stronger earnings leverage.
Guidance: Management raised full-year 2026 revenue guidance by $45 million and adjusted EBITDA guidance by $10 million, citing strong execution and confidence in the company’s operating leverage.
Pharma strength: Miebo and Xiidra both posted very strong growth, and management said the business has moved from launch mode into a revenue-and-profit growth phase.
Surgical reset: Surgical growth was below expectations because of weather disruption, reimbursement pressure, and a deliberate rebuild of the U.S. field force, but management expects sequential improvement through the year.
Consumer pipeline: PreserVision AREDS3 and Blink Triple Care launched in the quarter, while LUMIFY and Artelac continued to post strong growth, supporting the long-term consumer outlook.
